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Abstract
Introduction Recently, the Breast Cancer Association
Consortium (BCAC) conducted a multi-stage genome-wide
association study and identified 11 single nucleotide
polymorphisms (SNPs) associated with breast cancer risk.
Given the high degree of heritability of mammographic density
and its strong association with breast cancer, it was
hypothesised that breast cancer susceptibility loci may also be
associated with breast density and provide insight into the
biology of breast density and how it influences breast cancer
risk.
Methods We conducted an analysis in the Nurses' Health
Study (n = 1121) to assess the relation between 11 breast
cancer susceptibility loci and mammographic density. At the
time of their mammogram, 217 women were premenopausal
and 904 women were postmenopausal. We used generalised
linear models adjusted for covariates to determine the mean
percentage of breast density according to genotype.
Results Overall, no association between the 11 breast cancer
susceptibility loci and mammographic density was seen. Among
the premenopausal women, three SNPs (rs12443621 [TNRc9/
LOC643714], rs3817198 [lymphocyte-specific protein-1] and
rs4666451) were marginally associated with mammographic
density (p < 0.10). All three of these SNPs showed an
association that was consistent with the direction in which these
alleles influence breast cancer risk. The difference in mean
percentage mammographic density comparing homozygous
wildtypes to homozygous variants ranged from 6.3 to 8.0%.
None of the 11 breast cancer loci were associated with
postmenopausal breast density.
Conclusion Overall, breast cancer susceptibility loci identified
through a genome-wide association study do not appear to be
associated with breast cancer risk.
Introduction
Mammographic density is one of the strongest risk factors for
breast cancer. Women with 75% or more breast density are at
a four- to six-fold greater risk of breast cancer than women with
no density [1,2]. The mechanism by which mammographic
density increases breast cancer risk is unclear.
Results from twin studies have estimated that inherited
genetic influences account for 60 to 67% of the variation in
mammographic density [3]. Given its high degree of heritability
[3,4], a number of studies have examined genetic variation and
mammographic density utilising a candidate gene approach
focusing primarily on polymorphisms in oestrogen synthesis
and metabolising genes with inconclusive results [5-10]. In
addition, polymorphisms in growth factor genes – such as
insulin-like growth factor (IGF)-1 [11], IGF binding protein 3
[12] and pituitary growth hormone [13] – have been reported
to be associated with mammographic density, although these
findings have not yet been examined or replicated in independ-
ent studies.
Recently, the Breast Cancer Association Consortium (BCAC)
conducted a multi-stage genome-wide association study of
breast cancer cases and controls and identified 11 single
nucleotide polymorphisms (SNPs) associated with risk [14].
BCAC = Breast Cancer Association Consortium; BMI = Body mass index; CI = Confidence interval; FGFR2 = fibroblast growth factor receptor 2; 
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The Nurses' Health Study breast cancer nested case-control
study contributed to the third stage of this genome-wide asso-
ciation study. Given the strong association between mammo-
graphic density and breast cancer, breast cancer
susceptibility loci may also be associated with breast density
and provide insight into the biology of breast density and how
it influences breast cancer risk. We conducted a cross-sec-
tional study in the Nurses' Health Study (n = 1121) to assess
the relation between breast cancer susceptibility loci identified
from a multi-stage genome-wide association study and mam-
mographic density.
Materials and methods
The Nurses' Health Study was initiated in 1976, with 121,700
US-registered nurses age 30 to 55 years returning an initial
questionnaire [15]. Information on body mass index (BMI),
reproductive history, age at menopause and postmenopausal
hormone use, as well as diagnosis of cancer and other dis-
eases are updated every two years through questionnaires.
During 1989 and 1990, blood samples were collected from
32,826 women [16]. In general, blood samples were returned
within 26 hours of being drawn and were immediately centri-
fuged, aliquoted into plasma, red blood cells and buffy coat
fractions, and stored in liquid nitrogen freezers. The follow-up
rate among women who provided blood samples was 99%
through 1998.
We conducted a cross-sectional analysis among controls from
a breast cancer case-control study nested within the Nurses'
Health Study cohort. This nested case-control study included
breast cancer cases diagnosed after blood collection but
before 1 June 1998 and matched controls [17]. The collection
of film mammograms was targeted to breast cancer cases and
matched controls through the 1998 follow-up cycle. We col-
lected mammograms taken as close as possible to the date of
blood collection (1989 to 1990). This collection has been
described in detail in a previous publication [11].
This study was approved by the Committee on the Use of
Human Subjects in Research at Brigham and Women's Hos-
pital.
To assess mammographic density, the craniocaudal views of
both breasts were digitised at 261 microns/pixel with a Lumy-
sis 85 laser film scanner, which covers a range of 0 to 4.0 opti-
cal density. The software for computer-assisted thresholding
was developed at the University of Toronto [18] and this meas-
ure of mammographic breast density was highly reproducible
within this study [19]. We used the average percentage den-
sity of both breasts for this analysis. We also evaluated the
association of these SNPs with the absolute area of mammo-
graphic density, but because results were similar and percent-
age breast density has been a stronger predictor of breast
cancer risk than area of dense tissue in many [1,20-23] but not
all [24] studies, we present the results for percentage mam-
mographic density as our primary analyses and include the
association with dense and non-dense area in supplementary
tables.
As part of the third stage of the BCAC multi-stage genome-
wide association study, 30 SNPs were genotyped in the
Nurses' Health Study breast cancer nested case-control sam-
ples. Although genotype data are available for all 30 SNPs, we
present results for the 11 SNPs reported to be associated
with breast cancer after all three stages as our primary results.
Analyses examining the association between the other 19
SNPs and breast density were considered secondary (see
supplementary table 1 in additional data file 1).
Genotyping was conducted using a fluorescent 5' endonucle-
ase assay and the ABI-PRISM 7900 (Taqman) for sequence
detection. For quality control, about 10% of samples were
Table 1
Descriptive characteristics of study population (n = 1121) at the 
time of mammography, Nurses' Health Study (1989–1998)
Characteristic
Mean values Mean SD
Age, y 58.4 7.3
Body mass index, kg/m2 25.6 4.6
Percentage mammographic density, % 27.1 20.6
Frequenciesa N%
Menopausal/hormone status
Premenopausal 217 19.4
Postmenopausal/never user 371 33.1
Postmenopausal/past user 317 28.3
Postmenopausal/current user 216 19.3
Alcohol consumption
None 327 31.8
<5 g/day 346 33.6
5 to 14.9 g/day 221 21.5
15+ g/day 135 13.1
Parity/age at first birth
Nulliparous 83 7.5
Parous/<25 years 549 49.6
Parous/25 to 29 years 382 34.5
Parous/>30 93 8.4
Prior benign breast disease 465 41.5
Family history of breast cancer 135 12.0
a Numbers may not be added to total due to missing data.Available online http://breast-cancer-research.com/content/10/4/R66
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included as blinded duplicates in the genotyping runs. The
concordance for replicate samples was more than 99%.
We used generalised linear models adjusted for covariates to
determine the mean percentage breast density according to
genotype. To determine if there was a linear trend with increas-
ing variant alleles, we calculated p values from Wald statistics
including an ordinal variable for genotype regressed on square
root transformed percentage mammographic density. Covari-
ate information at the time of the mammogram was assessed
using data from biennial questionnaires completed before the
date of the mammogram. Although it is unlikely that these fac-
tors are confounders of the genotype and mammographic
density relationship, these variables do explain the substantial
variation in the outcome. In addition, genetic variants may be
associated with mammographic density through its associa-
tion with other covariates, such as BMI. Because our goal was
to determine if breast cancer susceptibility loci are associated
with mammographic density independent of factors know to
influence breast density, we included known predictors of
mammographic density in multivariate models.
Percentage mammographic density is considerably lower in
postmenopausal women than in premenopausal women. It has
been suggested that premenopausal breast density may be
more highly heritable than postmenopausal density [25], and
that different genes may be associated with premenopausal
density rather than with postmenopausal density [26]. We
therefore a priori considered that genes may differentially be
associated with premenopausal and postmenopausal mam-
mographic density. Because there was evidence that the
association between some of the breast cancer susceptibility
loci and breast density varied according to menopausal status
at mammogram we included results stratified by menopausal
status. Data analysis was conducted using SAS statistical
software version 9.1. All p values presented are two-sided
tests of statistical significance.
Results
This study examined the association between 11 breast can-
cer susceptibility loci and mammographic density in 1121
women in the Nurses' Health Study. The mean age of partici-
pants at the time of mammography was 58.4 years (Table 1).
At the time of their mammogram, 217 women were premeno-
pausal, with a mean (SD) age at mammography of 49.1 (3.3)
years. Among premenopausal women, the mean percentage
mammographic density was 39.7 (22.2)% (range 0.6 to
90.3%). At the time of their mammogram, 904 women were
postmenopausal with a mean age at mammography of 60.6
(6.2) years. Among postmenopausal women, the mean per-
centage mammographic density was 24.1 (19.0)% (range 0.0
to 86.5%). Of the postmenopausal women, 41% had never
used postmenopausal hormones, 24% were currently using
postmenopausal hormones and 35% were former users at the
time of their mammograms. European ancestry was self-
reported by 98.8% of the women in the study.
Overall, there was no significant association between the 11
breast cancer susceptibility loci and mammographic density
(Table 2). Of the 11 breast cancer susceptibility loci, three
were associated with premenopausal mammographic density
at p < 0.10 (Table 3). The variant allele of rs12443621
(TNRc9/LOC643714) was positively associated with mam-
mographic density; the mean percentage mammographic den-
sity among homozygous variants (42.5%) was 6.3%
percentage points greater than those homozygous for the
wildtype allele (36.2%). This association was primarily due to
the association with dense area (p = 0.04; see supplementary
Table 2 in additional file 2), rather than non-dense area (p =
0.30; see supplementary Table 3 in additional file 3). The vari-
ant allele of rs3817198 (lymphocyte-specific protein-1
[LSP1]) was positively associated with mammographic den-
sity; the mean percentage mammographic density among
homozygous variants (41.0%) was 7.5% percentage points
greater than those homozygous for the wildtype allele
(33.5%). This association also appears to be due to the asso-
ciation with dense area (p = 0.04; see supplementary Table 2
in additional file 2), rather than with non-dense area (p = 0.15;
see supplementary Table 3 in additional file 3). The variant
allele of rs4666451 was inversely associated with mammo-
graphic density; the mean percentage mammographic density
among homozygous variants (33.6%) was 8.0% percentage
points lower than those homozygous for the wildtype allele
(41.6%). In contrast, this association was primarily due to the
association with non-dense area (p-trend = 0.02; see supple-
mentary Table 3 in additional file 3), rather than with dense
area (p-trend = 0.22; see supplementary Table 2 in additional
file 2). None of the 11 breast cancer loci were associated with
postmenopausal breast density (Table 3). We also conducted
secondary analyses among postmenopausal women
restricted to women who were not taking postmenopausal
hormones at the time of mammography (n = 688). In general,
these results were consistent with results among all postmen-
opausal women (data not shown).
In a secondary analysis, we examined the 19 additional SNPs
that were genotyped in this study population as part of stage
3 of the genome-wide association study (see supplementary
Table 1 in additional file 1) but were reported to not be signif-
icantly associated with breast cancer after the final stage. Two
of these SNPs (rs6843340 and rs2298075) were associated
with mammographic density in the population overall.
rs6843340 was associated with both premenopausal and
postmenopausal density, while rs2298075 was associated
with only postmenopausal density (see supplementary Table 4
in additional file 4). In addition, rs10508468 was associated
with premenopausal breast density and rs6469633 was asso-
ciated with postmenopausal breast density only (see supple-
mentary Table 4 in additional file 4).Breast Cancer Research    Vol 10 No 4    Tamimi et al.
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Table 2
Mean percentage of mammographic density (MD) according to breast cancer susceptibility loci, Nurses' Health Study controls (1989 
to 1998)
NM e a n  % M D a Mean %MDb
rs2981582 G/G 421 26.9 26.7
G/A 539 26.9 26.6
A/A 160 26.8 28.0
p value d 0.56 0.98
rs12443621 A/A 298 25.0 25.7
A/G 561 27.3 26.9
G/G 267 27.4 27.1
p value d 0.12 0.25
rs13281615 A/A 377 27.6 27.2
A/G 553 25.9 26.3
G/G 198 28.1 27.5
p value d 0.90 0.91
rs3817198 A/A 489 26.0 25.9
A/G 491 27.8 27.8
G/G 119 25.9 26.1
p value d 0.95 0.79
rs889312 T/T 622 28.3 28.2
T/G 428 24.7 25.1
G/G 76 28.6 27.3
p value d 0.12 0.06
rs4666451 G/G 405 26.9 27.4
A/G 531 27.2 26.7
A/A 184 25.7 25.8
p value d 0.43 0.13
rs2107425 G/G 572 27.5 27.5
G/A 440 25.8 25.8
A/A 108 26.7 26.3
p value d 0.39 0.24
rs981782 A/A 336 27.9 27.0
A/C 544 26.5 26.9
C/C 231 26.7 26.8
p value d 0.15 0.40
rs8051542 G/G 307 26.8 26.8
G/A 383 25.7 25.6
A/A 173 29.3 29.2
p value d 0.67 0.64
rs30099 C/C 929 26.9 27.0
C/T 193 26.0 25.5Available online http://breast-cancer-research.com/content/10/4/R66
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Discussion
In this study, we found that overall none of the breast cancer
susceptibility loci were associated with mammographic den-
sity. However, some breast cancer susceptibility loci were
associated with premenopausal breast density. We did not
observe an association between any of these loci and post-
menopausal breast density. These loci were originally identi-
fied from a three-stage genome-wide association study. The
first stage of the genome-wide association study was among
390 breast cancer patients selected with a strong family his-
tory of breast cancer of at least two affected first-degree family
relatives and 364 controls [14]. Women with a family history
are more likely to develop breast cancer at an early age. It is
known that some breast cancer risk factors are differentially
associated with premenopausal and postmenopausal breast
cancer [27], hence it may be the case that the specific gene
contribution to density may also vary by menopausal status.
However, multiple lines of evidence suggest that the determi-
nants of breast density may differ at different ages [26,28,29].
Thus, it is possible that different sets of genetic variants may
be highly associated with premenopausal and postmenopau-
sal breast density. If this is the case it may explain why these
SNPs were associated with premenopausal breast density
only and not postmenopausal breast density.
A limitation of the current study is the relatively small number
of premenopausal women with density measurements (n =
217). Given the number of tests conducted, it is possible that
these findings are the result of chance. However, the direction
and strength of the association observed between the three
polymorphisms and premenopausal mammographic density
suggest that these genes may play an important role in deter-
mining premenopausal breast density. All three associated
SNPs are consistent with the direction in which these alleles
influence breast cancer risk [14]. The variant alleles of both
rs12443621 and rs3817198 were associated with increasing
breast density in this study and with increasing breast cancer
risk in the BCAC (Odds ratio [OR] for rs12443621
homozygous variant vs homozygous wildtype = 1.23, 95%
confidence interval [CI] 1.17 to 1.30 [14]; OR for rs3817198
homozygous variant vs homozygous wildtype = 1.17, 95%CI
1.08 to 1.25 [14]). The variant allele of rs4666451 was
inversely associated with breast density and with a reduced
risk of breast cancer in the genome-wide association study
(OR homozygous variant vs homozygous wildtype = 0.93,
95%CI 0.87 to 0.99) [14]. In addition, the difference in mean
percentage mammographic density comparing homozygous
wildtypes to homozygous variants ranged from 6.3 to 8.0 per-
centage points. These differences in mammographic density
are in the same range that has been associated previously with
changes in mammographic density observed with exposure to
postmenopausal hormones[30,31] and tamoxifen [32]. It is
estimated that a 5% higher mammographic density is associ-
ated with a 7% increase in breast cancer risk [1]; thus, the
estimated risk of breast cancer associated with these three
SNPs, and attributable to their influence on mammographic
density, would therefore range from 1.09 to 1.12.
Two of the three SNPs associated with premenopausal breast
density are in known genes: TNRc9/LOC643714
(rs12443621) and LSP1. It is unclear what the function of the
TNRc9 (also known as TOX3) gene is; however, it contains a
putative high mobility group box motif which suggests that it
may act as a transcription factor and this gene has been impli-
cated in breast cancer metastasis to the bone [33]. Another
variant in the TNRc9 gene (rs3803662) also emerged from an
independent genome-wide association study of oestrogen-
receptor positive breast cancer in an Icelandic population
[34]. rs3817198 in the LSP1 gene (also known as WP43) is
a cytoskeletal protein expressed in haematopoietic and
endothelial cells. rs4666451 is located on 2p with no known
gene function, although the region did appear in genome-wide
linkage analyses of familial breast cancer [35]. It remains to be
seen whether these SNPs exhibit their influence on breast
T/T 8 28.0 24.0
p value d 0.81 0.28
rs3803662 G/G 590 26.2 26.4
G/A 434 27.5 26.9
A/A 90 27.1 28.6
p value d 0.53 0.37
aAge adjusted.
bMultivariate adjusted for the following: age (continuous), body mass index (BMI) (continuous), alcohol consumption (none, <5 g/day, 5 to 14.9 g/
day, 15+ g/day), age at first birth/parity (nulliparous, age at first birth <25, age at first birth 25 to 29, age at first birth >30), history of benign breast 
disease (yes/no), family history of breast cancer (yes/no).
cMultivariate adjusted for the following: age, BMI, alcohol consumption, age at first birth/parity, history of benign breast disease, family history of 
breast cancer, postmenopausal status/hormone use (premenopausal, never user, current user, past user).
dp value based on genotype coded as ordinal variable regressed on square root transformed MD.
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Table 3
Mean percentage mammographic density (MD) according to breast cancer susceptibility loci, Nurses' Health Study controls 
(1989–1998)
Premenopausal (n = 217) Postmenopausal (n = 904)
N Mean %MDa Mean %MDb N Mean %MDa Mean %MDc
rs2981582 G/G 73 37.4 37.9 332 24.4 24.2
G/A 112 40.5 40.7 407 23.9 23.6
A/A 28 41.7 38.4 131 23.7 25.3
p value d 0.27 0.62 0.34 0.82
rs12443621 A/A 51 36.0 36.2 236 22.9 23.4
A/G 104 38.9 39.1 442 24.5 24.2
G/G 54 43.7 42.5 202 23.5 23.8
p value d 0.05 0.06 0.70 0.72
rs13281615 A/A 70 39.7 38.2 290 25.2 25.0
A/G 94 36.0 38.2 445 23.7 23.9
G/G 47 45.8 43.1 144 22.9 22.8
p value d 0.45 0.52 0.36 0.32
rs3817198 A/A 80 33.9 33.5 396 24.2 24.0
A/G 106 42.6 42.3 368 24.4 24.6
G/G 20 39.5 41.0 93 22.7 22.8
p value d 0.04 0.01 0.39 0.56
rs889312 T/T 107 41.1 41.3 499 25.6 25.4
T/G 89 38.5 38.2 321 21.5 22.1
G/G 14 38.8 37.2 58 26.8 25.3
p value d 0.40 0.21 0.17 0.14
rs4666451 G/G 74 40.7 41.6 314 24.0 24.5
A/G 96 40.6 39.5 418 24.2 23.8
A/A 36 33.0 33.6 144 24.3 24.3
p value d 0.13 0.06 0.90 0.40
rs2107425 G/G 105 41.7 40.7 449 24.3 24.6
G/A 87 36.8 37.2 337 23.4 23.3
A/A 18 37.5 39.6 85 24.6 23.6
p value d 0.11 0.29 0.79 0.37
rs981782 A/A 64 37.7 37.5 258 25.5 24.6
A/C 100 39.4 39.2 429 23.7 24.1
C/C 47 42.3 42.5 175 23.2 23.4
p value d 0.39 0.27 0.08 0.22
rs8051542 G/G 63 41.0 40.5 234 23.2 23.4
G/A 73 40.0 40.1 296 22.3 22.3
A/A 32 37.9 37.8 137 27.6 27.3
p value d 0.58 0.65 0.36 0.43
rs30099 C/C 175 38.8 38.8 723 24.4 24.5Available online http://breast-cancer-research.com/content/10/4/R66
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cancer risk through mammographic density. Because these
SNPs are associated with modest associations in breast can-
cer risk, larger studies with premenopausal density measure-
ments on breast cancer cases and controls will be necessary
to address this question.
SNPs in intron 2 of fibroblast growth factor receptor 2
(FGFR2) have emerged as top hits from multiple genome-wide
association studies of breast cancer [14,36]. We did not
detect an association between an FGFR2 (rs2981582) SNP
and breast density in the current study. Homozygous variants
of rs2981582 or other SNPs in high linkage disequilibrium are
estimated to confer about a 60% increase in breast cancer
risk relative to homozygous wildtypes [14,36]. Assuming the
association between FGFR2 variants and breast cancer is
mediated through breast density, one would expect to see a
33% difference in mammographic density comparing
homozygous variants with homozygous wildtypes. The current
study consisted of sufficiently high numbers of both premeno-
pausal and postmenopausal women to detect such a differ-
ence. The lack of association of the SNP in FGFR2 and other
breast cancer loci with breast density in this study suggests
that some genes influence breast cancer risk independent of
breast density.
Our primary analyses focused on the 11 SNPs identified after
a multi-stage genome-wide association study with p ≤ 0.001
in the combined analysis. We also examined 20 additional
SNPs that were either no longer significant at this cutoff or not
consistent with the direction originally observed. There is sug-
gestive evidence that three of these SNPs (rs2298075,
rs684340 and rs6469633) are associated with breast density
in a direction consistent with the observed association with
breast cancer risk. The p value in the combined BCAC study
for these three SNPs ranged from 0.002 to 0.13. Thus
although they were not considered significantly associated
with breast cancer at the defined cutoff, their borderline signif-
icance with breast cancer risk and consistent association with
breast density warrant further investigation of these SNPs in
relation to breast density and breast cancer risk.
To our knowledge, this is the first study to examine the associ-
ation between these replicated breast cancer susceptibility
loci and mammographic density in a cancer-free population.
Lee and colleagues [37] genotyped six breast cancer suscep-
tibility loci identified from genome-wide association studies
among 516 young (<50 years of age) breast cancer patients.
Five of these six SNPs were included in the present study.
Overall, they observed no association between the SNPs and
mammographic density. However, among women with oestro-
gen-receptor positive breast cancer rs3817198 was associ-
ated with mammographic density (p = 0.02). The direction of
the association observed was consistent with our findings
among premenopausal women.
The majority of the current study population was postmeno-
pausal at the time of mammography and we were limited by
the number of premenopausal women with breast density
measurements. Given that the first stage of the genome-wide
association study was among women with a strong family his-
tory, these SNPs may be more likely to be associated with pre-
menopausal density. It remains to be seen whether other
breast cancer susceptibility loci from other study designs are
associated with postmenopausal breast density.
Conclusion
Overall, breast cancer susceptibility loci identified through a
genome-wide association study do not appear to be associ-
ated with breast cancer risk.
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C/T 34 40.5 39.9 151 22.6 22.4
T/T 0 8 26.0 21.8
p value d 0.45 0.51 0.49 0.16
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day, 15+ g/day), age at first birth/parity (nulliparous, age at first birth <25, age at first birth 25 to 29, age at first birth >30), history of benign 
breast disease (yes/no), family history of breast cancer (yes/no).
cMultivariate adjusted for the following: age, BMI, alcohol consumption, age at first birth/parity, history of benign breast disease, family history of 
breast cancer, postmenopausal hormone use (never user, current user, past user).
dp value based on genotype coded as ordinal variable regressed on square root transformed MD.
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